DENND4C

Across TCGA pan-cancer cohorts, DENND4C Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated DENND4C data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher DENND4C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DENND4C expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and LUSC are the cancer types where DENND4C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.166	0.580	<.001	34	view →
UCEC	DFS	Median	All	0.941	0.602	.001	16	view →
LUSC	DFS	Median	III,IV	0.079	0.658	<.001	12	view →
HNSC	OS	Median	IV	0.162	0.639	.030	6	view →
BLCA	OS	Median	III,IV	0.069	0.582	<.001	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
LUAD	DFS	Median	All	0.242	0.815	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

DENND4C–BRCA (OS)

Open the BRCA breakdown →